Portfolio Company · Operating Co.

Prolong Pharmaceuticals

Biopharmaceutical · Website

backed byTarsadia Investments

CurrentBiopharmaceutical

a portfolio company of

Tarsadia Investments

Status on record: Current

Investment year: 2009

PE Firm Index

Who owns Prolong Pharmaceuticals?

Prolong Pharmaceuticals is listed as a current portfolio company of Tarsadia Investments on Tarsadia Investments' own portfolio page. Tarsadia Investments has owned Prolong Pharmaceuticals since 2009, per Tarsadia Investments' portfolio page.

From the company's website

Oxygen delivery therapies that protect the brain during Acute Ischemic Stroke.

Source: prolongpharma.com, read November 2026

Company Snapshot

Prolong Pharmaceuticals is a Biopharmaceutical company. Its owner on record, Tarsadia Investments, is a firm. Tarsadia Investments lists 32 companies in the index, 12 of them in Biopharmaceutical.

SectorBiopharmaceutical

Parent PE firmTarsadia Investments

Ownership statusCurrent

WebsiteVisit ↗

About the owner

Tarsadia Investments

Companies in the index: 32

Private investment firm investing across public and private markets.

Read the Tarsadia Investments profile

Questions about Prolong Pharmaceuticals

Who owns Prolong Pharmaceuticals?

What sector is Prolong Pharmaceuticals in?

Prolong Pharmaceuticals is in Biopharmaceutical. Classified from the owner's portfolio label.

What else does Tarsadia Investments own in Biopharmaceutical?

Tarsadia Investments lists 11 other Biopharmaceutical companies in the index, including Amneal Pharmaceuticals, Asana Biosciences, AvantStay, ChronicleBio and ClinTrial Research.

What is Prolong Pharmaceuticals' website?

Prolong Pharmaceuticals' website is https://www.prolongpharma.com/.

Sources

Tarsadia Investments
https://tarsadia.com/portfolio

This profile is based on publicly available information and may be incomplete or outdated. PE Firm Index is not affiliated with Prolong Pharmaceuticals and does not provide investment advice.

Other portfolio companies of Tarsadia Investments

6 of 31 shown

Amneal Pharmaceuticals

Pharmaceuticals

Asana Biosciences

Life Sciences / Biotech

AvantStay

Real Estate / Hospitality

See the full Tarsadia Investments portfolio.

Other Biopharmaceutical companies held by Tarsadia Investments

Amneal Pharmaceuticals Asana Biosciences

AvantStay ChronicleBio

ClinTrial Research Erasca

Other Biopharmaceutical portfolio companies

via Wavemaker 360 Health

3P Biopharmaceuticals

via Marlin Equity Partners

Browse PE-backed companies.

Is this your company?

Claiming is free and reviewed by hand. Correct facts and add your team.

Claim this profile Suggest a correction

Ownership

Parent PE firm

Tarsadia Investments

Status: Current

Investment year: 2009

Check this company's website

Check this company's website now

Free, in about two minutes: the verified issues a buyer or a customer's browser would meet. Runs on GTM Brain, by DevriX.

Observational measurements of this company's public website only. Not a rating of the company, its performance, its management, or its investment merit. Not investment advice. Request a correction or removal via Submit Update.

For PE-backed companies

DevriX

DevriX runs the websites, integrations and data that bring in revenue, as one accountable engineering and operations team, through acquisitions and exit.

Where DevriX helps

Value creation through the holdRevenue, data, web and AI run as one operating cadence, tied to EBITDA.Add-ons and carve-outsConsolidate or separate platforms and unify reporting after a deal.Exit readinessFind the technology and data issues a buyer's diligence would raise, before it does.

Send DevriX a short brief

A short form on devrix.com. No call to book.

Disclosure: PE Firm Index is maintained by Mario Peshev, who founded and runs DevriX. DevriX listing

Weekly PE M&A and market research, by email

The Growth Shuttle Insider is Mario Peshev's weekly newsletter for PE owners and operators. Each issue carries the week's private equity deals from this index, market data and research, and an essay from Mario.

Free. One email a week. Unsubscribe from any issue. Your address goes to beehiiv, the service that sends the Insider.

Research

The 2027 Digital Value Creation Baseline

1,407 PE-backed companies from 179 sponsors, measured from public sources in October 2026. 15% of service and product companies have the full path from search to CRM.

Read the research

Research by Growth Shuttle and DevriX.